68th ASH Annual Meeting 2026 (New Orleans, USA)
Overview of CML related sessions

Timings in Central Standard Time (CST)

Time slots	Sessions
1 - Scientific Sessions at ASH	
Scientific Workshops (*for in-person participants only*)	

Dec 11 (Friday)
 	
2.00 – 6.00 p.m.
 	
MCCNO –
220 - 222
	Scientific Workshop on myeloid development
	
	Co-Chairs:
	• Patricia Ernst (Denver, USA)
	• Ulrich Steidl (New York, USA)
	
	Program:
	• Opening remarks: Patricia Ernst (Denver, USA)
	• Stem cells
	  ○ Eric Pietras (University of Colorado, USA) - Moderator
	  ○ Peroxisomal B-Oxidation constraints hematopoietic stem cell regeneration
	  ○ Isogenic mice housed under SPF conditions achieve highly divergent aged hematopoietic phenotypes, defined by differing inflammatory signaling states
	  ○ Irradiation-resistant bone marrow macrophages regulate HSC homing via CXCR4 transfer
	  ○ Chronic inflammatory remodeling of the bone marrow niche enforces a stress-adapted hematopoietic stem cell state in sickle cell disease
	  ○ Hematopoietic stem cells are targets rather than initiators of CD4+ T cell responses

The International CML Foundation is registered as charity no. 1132984 in England and Wales
Registered Address: International CML Foundation - 20 Eversley Road - Bexhill-On-Sea, East Sussex, TN40 1HE - UK
Board of Directors: J Cortes (Chair) – J Apperley - B Druker - A Hochhaus – T Hughes – H Malhotra – M Mauro –
K Pagnano – J Radich – G Saglio – C Schiffer
E-Mail: info@cml-foundation.org, Web:www.cml-foundation.org

Time slots	Sessions
	○ Macropinocytosis may support hematopoietic stem cell nutrient sensing and self-renewal • Transcription and Epigenetics ○ Kathrin Bernt (Children's Hospital of Philadelphia, USA) – Moderator ○ Disrupting a convergent acetylation circuit collapses leukemic identity across AML subtypes ○ Enhancer-state coherence as a determinant of clonal fitness and myeloid transformation ○ The non-canonical NUP98::LNP1 fusion drives leukemic transformation via charge- and domain-based protein interactions ○ METTL3 inhibition disrupts R-loop homeostasis and activated the cGAS-STING pathway in acute myeloid leukemia ○ Using multiomic and functional experiments in mouse models to study the observation that patients with donor-derived DNMT3A mutant clonal hematopoiesis have a decreased risk of AML relapse ○ TET2-mutant clonal hematopoiesis regulates solid tumour metastasis • Signaling and developmental hematopoiesis ○ Kira Gritsman (Albert Einstein College of Medicine, USA) - Moderator ○ Embryo-derived bone marrow macrophages regulate HSC heterogeneity over lifetime ○ Wnt signaling in HSPCs couples macrophage differentiation with phagocytic function ○ Targeting CoREST complex to restrict menin inhibitor induced monocytic lineage plasticity in AML ○ Erythroid bias and inflammatory hypersensitivity in trisomy 21 blood stem cells and myeloid leukemia ○ Characterization of a novel KIT mutant model of systemic mastocytosis ○ Novel forward-engineered model of CMML demonstrates potent activity of multi-selective

The International CML Foundation is registered as charity no. 1132984 in England and Wales
Registered Address: International CML Foundation - 20 Eversley Road - Bexhill-On-Sea, East Sussex, TN40 1HE - UK
Board of Directors: J Cortes (Chair) – J Apperley - B Druker - A Hochhaus – T Hughes – H Malhotra – M Mauro –
K Pagnano – J Radich – G Saglio – C Schiffer
E-Mail: info@cml-foundation.org, Web:www.cml-foundation.org

Time slots	Sessions

	RAS(ON) inhibition
	• Myeloid malignancies
	  ○ Zuzana Tothova (Dana-Farber Cancer Institute, USA)
	  ○ QKI derives m7G-dependent monocytic resistance and immune evasion in AML
	  ○ Ubiquitin-dependent regulation of inflammatory signaling creates a therapeutic vulnerability in Myeloproliferative Neoplasms
	  ○ Nucleolar remodeling by DDX54 drives normal and neoplastic hematopoiesis
	  ○ Identification of chromosomal lesion-specific drivers of leukemia cell states in TP53-mutant AML by single cell RNA-sequencing
	  ○ Leukemia stem cell expansion cultures unveil clonal determinants of fitness and therapy response
	  ○ Somatic mitochondrial DNA mutations in clonal hematopoiesis

Education Program Sessions	
Dec 12 (Saturday) 4.00 – 5.15 p.m. MCCNO – R06-R09	**Education Program Session:** Persistent challenges in managing chronic myelogenous leukemia Chair: Elisabetta Abruzzese (Rome, Italy) Speakers: • Update on CML-CP management: From choice of first-line therapy to treatment-free remission Akriti G Jain (Cleveland, USA) • Management of chronic myeloid leukemia in blast phase Andreas Hochhaus (Jena, Germany) • Treating CML during pregnancy Elisabetta Abruzzese (Rome, Italy)

The International CML Foundation is registered as charity no. 1132984 in England and Wales
Registered Address: International CML Foundation - 20 Eversley Road - Bexhill-On-Sea, East Sussex, TN40 1HE - UK
Board of Directors: J Cortes (Chair) – J Apperley - B Druker - A Hochhaus – T Hughes – H Malhotra – M Mauro –
K Pagnano – J Radich – G Saglio – C Schiffer
E-Mail: info@cml-foundation.org, Web:www.cml-foundation.org

Time slots	Sessions
Oral Abstract Sessions	
Dec 12 (Saturday) 9.30 – 11.00 a.m. MCCNO – Hall B	**Oral Abstract Session:** Chronic Myeloid Leukemia: Clinical and Epidemiological: Biomarkers, resistance, and the molecular frontier Moderators: • Delphine Réa (Paris, France) • Giuseppe Saglio (Turin, Italy) Program: • Displacement of ABL1 exon 10 through exon skipping or duplication signifies a new genomic mechanism of clinical resistance to the BCR::ABL1 allosteric tyrosine kinase inhibitor asciminib (Leyte-Vidal A et al.) (ID 91) • Association between TKI discontinuation and advanced-phase progression in TFR-eligible chronic myeloid leukemia: A multicenter retrospective cohort study (Lin T et al.) (ID 92) • Additional somatic mutations detected by serial single-molecule molecular inversion probe sequencing in a prospective cohort of newly diagnosed chronic myeloid leukemia: Insights on mutational dynamics from the prospective TCGA-GTA registry (Perusini M et al.) (ID 93) • Immune surveillance after a second TKI stop in CML: Dasatinib-associated CD4+ T-cell modulation and TFR duration – first findings from the DASTOP2 study (Pakize AK et al.) (ID 94) • Frontline therapy with tyrosine kinase inhibitors (TKIs) may modify the frequency of mutated ASXL1 and the cell lineage in blast phase (BP) CML: Insights from the International CML Foundation (iCMLf) Genomics Alliance on the HARMONY Platform (Branford S et al.) (ID 95) • Longitudinal myeloid-panel sequencing reveals a diverse spectrum of somatic mutation dynamics in asciminib-treated chronic myeloid leukemia (Patiño AF et al.) (ID 96)
Dec 14 (Monday)	**Oral Abstract Session**: Chronic Myeloid Leukemia: Clinical and Epidemiological: New drugs, new paradigms in CML

The International CML Foundation is registered as charity no. 1132984 in England and Wales
Registered Address: International CML Foundation - 20 Eversley Road - Bexhill-On-Sea, East Sussex, TN40 1HE - UK
Board of Directors: J Cortes (Chair) – J Apperley - B Druker - A Hochhaus – T Hughes – H Malhotra – M Mauro –
K Pagnano – J Radich – G Saglio – C Schiffer
E-Mail: info@cml-foundation.org, Web:www.cml-foundation.org

Time slots	Sessions
10.30 a.m. – 12.30 p.m. MCCNO R06 – R09	Moderators: • Agnes Yong (Adelaide, Australia) • Andreas Hochhaus (Jena, Germany) Program: • Preliminary results from the ALLG CML14 ascendance trial: Genomic risk-adapted frontline combination asciminib / dasatinib therapy may abrogate poor prognosis of additional genomic abnormalities in chronic phase CML (Yeung D et al.) (ID 799) • Updated long-term efficacy and safety of TGRX-678, a novel STAMP inhibitor, in heavily pre-treated TKI resistant/intolerant CML patients from Phase 1 study TGRX-678-1001 (Jiang Q et al.) (ID 800) • Sustained superior tolerability and patient-reported benefits with asciminib vs nilotinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Results from the ASC4START trial (Brümmendorf TH et al.) (ID 801) • CARDINAL: A phase 1/2 study of the novel investigational allosteric BCR::ABL1 inhibitor MK-4208 (TERN-701) in participants with previously treated CML (Jabbour E et al.) (ID 802) • Cardio- and cerebrovascular adverse events during olverembatinib therapy in chronic myeloid leukemia: Incidences, outcomes, and risk factors (Zhang X et al.) (ID 803) • Prognostic factors and long-term outcomes of patients receiving frontline TKI-based combination therapy for lymphoid blast phase chronic myeloid leukemia (Karrar O et al.) (ID 804)
Poster Presentations (*for in-person participants only*)	
Dec 12 (Saturday) 5.30 – 7.30 p.m. MCCNO – Hall F	**Poster Abstract Session**: Chronic myeloid leukemia: Clinical and epidemiological – Poster I Poster: • Genetic and clinical features for predicting tyrosine kinase inhibitor resistance and optimizing frontline therapy in chronic myeloid leukemia (Yan M et al.) (ID 1980)

The International CML Foundation is registered as charity no. 1132984 in England and Wales
Registered Address: International CML Foundation - 20 Eversley Road - Bexhill-On-Sea, East Sussex, TN40 1HE - UK
Board of Directors: J Cortes (Chair) – J Apperley - B Druker - A Hochhaus – T Hughes – H Malhotra – M Mauro –
K Pagnano – J Radich – G Saglio – C Schiffer
E-Mail: info@cml-foundation.org, Web:www.cml-foundation.org

Time slots	Sessions
	• A dasatinib-enhanced adaptive natural killer cell therapy against TKI-resistant blast crisis chronic myeloid leukemia (Krishnan V et al.) (ID 1981) • Kinetics, durability, and cumulative tyrosine kinase inhibitor exposure as predictors of treatment-free remission in chronic myeloid leukemia (Lee S et al.) (ID 1982) • Treatment-free remission in chronic myeloid leukemia: Outcomes after discontinuation of second- or later-line TKI therapy (Grano S et al.) (ID 1983) • Phase II trial of dasatinib in combination with ASTX727 in patients with newly diagnosed chronic myeloid leukemia (Medawar G et al.) (ID 1984) • Treatment-free remission after TKI discontinuation in pediatric and adolescent CML-CP: A multicenter retrospective study in China (Zu Y et al.) (ID 1985) • Asciminib once or twice daily demonstrates sustained efficacy, stable patient-reported outcomes, and favorable safety in patients with chronic myeloid leukemia resistant or intolerant to 2 or more tyrosine kinase inhibitors: Final results of the ASC4OPT study (Hochhaus A et al.) (ID 1986) • Week 96 interim analysis (IA) of efficacy and safety results in the phase 2 ASC2ESCALATE trial: Asciminib (ASC) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after 1 tyrosine kinase inhibitor (TKI) (Atallah E et al.) (ID 1987) • Efficacy and safety of vamotinib versus high-dose imatinib in patients with chronic-phase CML resistant to standard-dose imatinib: 24-month results of a multicenter randomized phase III study (Turkina A et al.) (ID 1988) • One-step single-molecule countable PCR enables cis/trans phasing of BCR-ABL1 compound mutations in TKI-resistant CML (Shang Y et al.) (ID 1989) • Loss of TFR predictive value of the OCTN1 (SLC22A4) rs460089 polymorphism in CML patients undergoing two phases of TKI dose de-escalation before treatment discontinuation: Results from the HALF study (Vajnerova R et al.) (ID 1990) • Global burden of chronic myeloid leukemia and attributable risk factors in 204 countries and

The International CML Foundation is registered as charity no. 1132984 in England and Wales
Registered Address: International CML Foundation - 20 Eversley Road - Bexhill-On-Sea, East Sussex, TN40 1HE - UK
Board of Directors: J Cortes (Chair) – J Apperley - B Druker - A Hochhaus – T Hughes – H Malhotra – M Mauro –
K Pagnano – J Radich – G Saglio – C Schiffer
E-Mail: info@cml-foundation.org, Web:www.cml-foundation.org

Time slots	Sessions
	territories from 1990 to 2021: Results from the global burden of disease study 2021 (Zhou Y et al.) (ID 1991) • A prospective study on the feasibility of treatment-free remission in patients with chronic myeloid leukemia: Success and challenges faced at a tertiary care center in India (Sengupta A et al.) (ID 1992) • Asciminib as front-line or later-line therapy in patients with chronic myeloid leukemia: A multicenter retrospective study from China (Yu L et al.) (ID 1993) • Impaired DNAM-1/NKp80 NK-cell activation and T-cell exhaustion at diagnosis precede suboptimal early molecular response in CML (Binelli LS et al.) (ID 1994) • Short-course pomalidomide for maintaining treatment-free remission CML-chronic phase after TKI discontinuation: Early results of an ongoing phase II trial (Jain H et al.) (ID 1995) • Association of somatic mutations with long-term outcomes of ponatinib treatment in chronic-phase chronic myeloid leukemia (Kulemina O et al.) (ID 1996) • Characterization of atypical breakpoints of BCR::ABL1 rearrangements in chronic myelogenous leukemia (CML) and other myeloid malignancies (Atallah E et al.) (ID 1997) • BCR::ABL1 positivity CD3+ T cells in peripheral blood predict early molecular response to TKI in newly diagnosed chronic myeloid leukemia (Zeng L et al.) (ID 1998)
Dec 13 (Sunday) 6.00 – 8.00 p.m. MCCNO – Hall F	**Poster Abstract Session**: Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II Poster: • Validation of a prognostic score in blast phase CML: A cure CML consortium analysis (Akriti JG et al.) (ID 3743) • Deep molecular response and treatment-free remission with dasatinib plus venetoclax in newly diagnosed chronic myeloid leukemia (Nassar D et al.) (ID 3744) • Long-term outcomes with vodobatinib in heavily pre-treated chronic phase CML: Phase 1/2

The International CML Foundation is registered as charity no. 1132984 in England and Wales
Registered Address: International CML Foundation - 20 Eversley Road - Bexhill-On-Sea, East Sussex, TN40 1HE - UK
Board of Directors: J Cortes (Chair) – J Apperley - B Druker - A Hochhaus – T Hughes – H Malhotra – M Mauro – K Pagnano – J Radich – G Saglio – C Schiffer
E-Mail: info@cml-foundation.org, Web:www.cml-foundation.org

Time slots	Sessions
	study analysis (Cortes J et al.) (ID 3745) • Mutagenesis and resistance screening identify novel kinase-activating mutations in the BCR region and demonstrate minimal resistance to the bosutinib-asciminib combination (Schwieterman J et al.) (ID 3746) • Pre-transplant disease control and residual risk after prior blast-phase chronic myeloid leukemia in patients undergoing allogeneic hematopoietic cell transplantation: A CIBMTR cohort analysis (Tangella AV et al.) (ID 3747) • Evaluating the pro-inflammatory and atherothrombotic profile in relation to long-term cardiovascular toxicity of nilotinib in chronic myeloid leukemia: 5-year update of the prospective kiaro study (Sicuranza A et al.) (ID 3748) • Clinicopathologic features, treatment patterns, and outcomes of adolescents and young adults with chronic myeloid leukemia in the current tyrosine kinase inhibitor era (Aubrey BJ et al.) (ID 3749) • Predictors of response among patients treated with asciminib as initial therapy for patients with chronic myeloid leukemia in chronic phase (ALERT CML) (Mauro M et al.) (ID 3750) • Predictors of successful treatment-free remission (TFR) in chronic myeloid leukemia: Results from two prospective tyrosine kinase inhibitor (TKI) discontinuation trials (Pagnano KB et al.) (ID 3751) • Preliminary efficacy and safety of HS-10382 monotherapy in newly diagnosed Ph+ CML-CP: A phase 1b study (Li W et al.) (ID 3752) • “Halve of nothing”: Different long-term management strategies of chronic myeloid leukemia in stable deep molecular response (Ginotto G et al.) (ID 3753) • Outcome of TKI discontinuation after allogeneic stem cell transplantation in patients with chronic myeloid leukemia (CML): A retrospective study from the CMWP of the EBMT (de Lavallade H et al.) (ID 3754) • XS003, ASD-nilotinib, reduces the risk of QTc prolongation at fed conditions (Darpö B et al) (ID 3755)

The International CML Foundation is registered as charity no. 1132984 in England and Wales
Registered Address: International CML Foundation - 20 Eversley Road - Bexhill-On-Sea, East Sussex, TN40 1HE - UK
Board of Directors: J Cortes (Chair) – J Apperley - B Druker - A Hochhaus – T Hughes – H Malhotra – M Mauro – K Pagnano – J Radich – G Saglio – C Schiffer
E-Mail: info@cml-foundation.org, Web:www.cml-foundation.org

Time slots	Sessions
	• Real-world outcome of newly diagnosed (ND) patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with BCR::ABL1 tyrosine kinase inhibitors (TKIs) (Blanc S et al.) (ID 3756) • Outcomes in clinical practice of using lower-than-standard dose asciminib for chronic myeloid leukemia (Yousefi A et al.) (ID 3757) • Hydroxyurea exposure during pregnancy in women with chronic myeloid leukemia: Maternal and fetal outcomes from a single center experience (Ishac R et al.) (ID 3758) • Primary analysis of asciminib in a novel pediatric formulation for pediatric chronic myeloid leukemia in chronic phase (CML-CP) in the phase 1b/2 ASC4Kids trial (Pollard JA et al.) (ID 3759) • From clinical observations to population-based evidence: Sex differences in work participation in young adults with chronic myeloid leukemia (Gjertsen BT et al.) (ID 3760) • Optimizing TKI dose de-escalation in chronic myeloid leukemia: Timing and predictive markers after major molecular response (Lee S et al.) (ID 3761)
Dec 14 (Monday) 6.00 – 8.00 p.m. MCNNO – Hall F	**Poster Abstract Session:** Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III Poster: • Different BCR::ABL1 transcript thresholds at 3 and 6 months may improve the identification of optimal warning, and resistant CP-CML patients treated with frontline 2G-TKIs (Stagno F et al.) (ID 5504) • A phase I/II study of azacitidine, venotoclax and olverembatinib for chronic myeloid leukemia in blast phase (Wang Y et al.) (ID 5505) • Safety and efficacy of TGRX-679 in newly diagnosed chronic phase chronic myeloid leukemia (Li Z et al.) (ID 5506) • Week 96 interim analysis (IA) of efficacy and safety in the phase 2 ASC2ESCALATE trial: Asciminib (ASC) in the first-line (1L) cohort of patients (pts) with chronic myeloid leukemia in

The International CML Foundation is registered as charity no. 1132984 in England and Wales
Registered Address: International CML Foundation - 20 Eversley Road - Bexhill-On-Sea, East Sussex, TN40 1HE - UK
Board of Directors: J Cortes (Chair) – J Apperley - B Druker - A Hochhaus – T Hughes – H Malhotra – M Mauro –
K Pagnano – J Radich – G Saglio – C Schiffer
E-Mail: info@cml-foundation.org, Web:www.cml-foundation.org

Time slots	Sessions
	chronic phase (CML-CP) (Levy M et al.) (ID 5507) • Long-term efficacy of flumatinib 600 mg and 400 mg for newly diagnosed chronic phase chronic myeloid leukemia: A phase 4 double-blind randomized dose-optimization trial (Li W et al.) (ID 5508) • Real-world outcomes and prognostic factors in pediatric chronic myeloid leukemia: A multicenter study from China (An W et al.) (ID 5509) • Co-occuring myeloid mutations are associated with TKI resistance and transformation in chronic-phase CML: A multicenter analysis (Iqbal U et al.) (ID 5510) • CD19-directed CAR T-cell therapy with brexucabtagene autoleucel or obecabtagene autoleucel produces durable remission for CML patients in lymphoid blast phase: A Rocca Consortium multicenter analysis (Cetin S et al.) (ID 5511) • Genetic anatomy of BCR::ABL1 and bone marrow genomic DNA digital PCR as a predictor of treatment-free remission in chronic myeloid leukemia (Ernst T et al.) (ID 5512) • Efficacy and safety of frontline asciminib in newly diagnosed chronic myeloid leukemia: Interim analysis of phase II trial (Khori MR et al.) (ID 5513) • Efficacy and renal function outcomes of first-line flumatinib in chronic myeloid leukemia: A prospective multicenter real-world analysis of dose-response and creatinine dynamics (Wang Q et al.) (ID 5514) • Heterogeneous effects of clonal hematopoiesis mutations detected at the time of discontinuation tyrosine kinase inhibitor on treatment-free remission in CML-CP patients (Yuk Man Cheung C et al.) (ID 5515) • Chronic graft-versus-host disease as a clinical marker of alloreactivity after allogeneic cell transplantation for chronic myeloid leukemia: A CIBMTR cohort analysis (Tangella AV et al.) (ID 5516) • Treatment-free remission and overall survival in chronic myeloid leukemia: A cure CML Consortium analysis (Jamy O et al.) (ID 5517) • Long-term outcomes of elderly CML patients (Age = 60 years) treatment with tyrosine kinase

The International CML Foundation is registered as charity no. 1132984 in England and Wales
Registered Address: International CML Foundation - 20 Eversley Road - Bexhill-On-Sea, East Sussex, TN40 1HE - UK
Board of Directors: J Cortes (Chair) – J Apperley - B Druker - A Hochhaus – T Hughes – H Malhotra – M Mauro – K Pagnano – J Radich – G Saglio – C Schiffer
E-Mail: info@cml-foundation.org, Web:www.cml-foundation.org

Time slots	Sessions
	inhibitors: Data from the hematological cancer consortium in India (Ghosh S et al.) (ID 5518) • Molecular burden beyond MMR at 12 months defines distinct response trajectories in chronic myeloid leukemia (Williams R et al.) (ID 5519) • Outcomes of patients with newly diagnosed chronic myeloid leukemia and ASXL1 mutations with dasatinib (Jabbour J et al) (ID 5520) • Multicenter real-world data of asciminib as second-line therapy in chronic myeloid leukemia treatment (Perusini M et al.) (ID 5521) • Characteristics and long-term outcomes of patients with chronic-phase chronic myeloid leukemia who received ponatinib for at least 5 years in the phase II OPTIC trial (McCloskey JK et al.) (ID 5522)
2- Additional CML meetings and events	
Dec 11 (Friday) 12 – 2.30 p.m. SpringHill Suites New Orleans Warehouse District, 301 Saint Joseph Street	**iCMLf Forum 2026:** From Promise to Practice: New Drugs, Formulations and Testing in CML *(for in-person participants only)* Chair: Tim Hughes (Adelaide, Australia) Topics: • Expanding the toolbox: Where new TKIs fit in CML (A. Hochhaus, Q. Jiang) • From tablet to tailored: Rethinking how TKIs are given (Speakers TBC) • Monitoring that fits: New tools for testing in CML (Speakers TBC)
Dec 11 (Friday) 11.00 a.m. – 2.00 p.m. MCCNO –	**Satellite Symposium:** CML treatment continuum: Optimizing therapy selection, molecular monitoring, and long-term quality of life This program is supported by Enliven Therapeutics Inc. and Novartis Pharmaceuticals Corporation. Developed through a strategic collaboration between H. Jean Khoruy CML Consortium and Medscape Oncology

The International CML Foundation is registered as charity no. 1132984 in England and Wales
Registered Address: International CML Foundation - 20 Eversley Road - Bexhill-On-Sea, East Sussex, TN40 1HE - UK
Board of Directors: J Cortes (Chair) – J Apperley - B Druker - A Hochhaus – T Hughes – H Malhotra – M Mauro –
K Pagnano – J Radich – G Saglio – C Schiffer
E-Mail: info@cml-foundation.org, Web:www.cml-foundation.org

Time slots	Sessions
Great Hall BC	Chair: Kendra L. Sweet (Tampa, USA) Speakers: • Ehab Atallah (Milwaukee, USA) • Michael Mauro (New York, USA) Program: This symposium will focus on the latest strategies to optimize CML therapy. The discussion will help clinicians sharpen treatment decisions across the CML continuum – from selecting the most appropriate first-line TKI to navigating molecular failure, resistance, and long-term sequencing. Faculty will also discuss practical strategies to manage chronic toxicities and support treatment-free remission eligibility, along with a look at promising pipeline agents that may shape the future of CML care.
Dec 13 (Sunday) 6.00 – 10.00 a.m. Astor Crown Plaza, 739 Canal Street (at Borbon Street)	**ELN Breakfast Meeting**: WP4 (Chronic myeloid leukemia) *(for in-person participants only)* Chairs: • Weiming Li (Wuhan, China) • Giuseppe Saglio (Turin, Italy) Program: • A phase I/II study of azacitidine, venetoclax and olverembatinib in blast phase (Liu B.) • Association of baseline somatic co-mutation burden with inferior TKI efficacy and clonal progression: A real-world cohort study (Zhu Y.) • Real-world study on TFR in China (Li W.) • Prognostic factors of TFR from TKI STOP studies in Japan (Takahashi N.)

The International CML Foundation is registered as charity no. 1132984 in England and Wales
Registered Address: International CML Foundation - 20 Eversley Road - Bexhill-On-Sea, East Sussex, TN40 1HE - UK
Board of Directors: J Cortes (Chair) – J Apperley - B Druker - A Hochhaus – T Hughes – H Malhotra – M Mauro –
K Pagnano – J Radich – G Saglio – C Schiffer
E-Mail: info@cml-foundation.org, Web:www.cml-foundation.org

Time slots	Sessions
	• The new CML clinical guideline in Japan: JSH guideline version 4, 2026 (Minami Y.) • TFR data in routine clinical practice in Brasil (Pagnano K.) • TFR data in routine clinical practice in Italy (Fava C.) • Co-variates correlated with success of TFR cytokines (Jiang Q.) • Cytokines, NK cells, and clinical predictors of molecular relapse in CML (Pavlovsky C.) • Discussion

The International CML Foundation is registered as charity no. 1132984 in England and Wales
Registered Address: International CML Foundation - 20 Eversley Road - Bexhill-On-Sea, East Sussex, TN40 1HE - UK
Board of Directors: J Cortes (Chair) – J Apperley - B Druker - A Hochhaus – T Hughes – H Malhotra – M Mauro –
K Pagnano – J Radich – G Saglio – C Schiffer
E-Mail: info@cml-foundation.org, Web:www.cml-foundation.org